Compare VNET Group Inc (VNET) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VNET Group Inc vs Viatris Inc — how do they compare? VNET Group Inc trades at $7.52 (market cap $2.14B), while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: Viatris Inc is far larger — about 8.7× VNET Group Inc's market cap, and Viatris Inc pays a 2.95% dividend while VNET Group Inc pays none. Which is the better fit depends on your goals.
| VNET | VTRS | |
|---|---|---|
Market Cap | $2.14B | $18.69B |
Sector | Technology | Health |
52-Week High | $14.03 | $17.86 |
52-Week Low | $6.29 | $9.49 |
Enterprise Value | $5.29B | $30.80B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VNET Group trades at $7.425, down 0.74% on the day, with a neutral technical signal and mixed earnings history. The stock shows a price-to-sales ratio of 1.32 and an EV/EBITDA of 26.51, but profitability remains weak with a net income margin of -21.63% and negative ROE. Recent news highlights large call option purchases and upcoming Q2 2026 earnings on August 18, 2026, amid strategic investor involvement.
The outlook is cautiously optimistic due to strong analyst buy ratings (62.5%) and AI-driven demand growth, but significant risks include persistent losses, high debt levels, and competitive pressures in China's data center market. Investors should weigh the potential from new capacity against execution challenges.
Viatris (VTRS) trades at $16.105, down 1.07% on the day, with a bearish technical signal and mixed fundamentals. Recent Q2 2026 earnings beat estimates with EPS of $0.69 and revenue growth of 5%, but the company posted a net loss of $3.51B in 2025. Positive developments include FDA approval for Gwyn Lo and a raised 2026 outlook, though debt remains elevated at $14.04B long-term.
Outlook is cautious; while operational cash flow is strong at $2.32B and dividends provide income, persistent net losses and high P/E of 236.2 signal overvaluation risks. Analyst consensus leans Hold (61.54%), with upside potential if turnaround gains traction, but investors face headwinds from generic drug pricing pressures and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About VNET Group Inc
VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
